Mirum Pharmaceuticals Inc. (MIRM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Mirum Pharmaceuticals Inc. (MIRM) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How MIRM Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $521.3M | 44% | -4.2% | -$23.4M | $54.9M | -6.8% |
| FY 2024 | $336.9M | 44% | -26% | -$87.9M | $9.3M | -34% |
| FY 2023 | $186.4M | 44% | -58.6% | -$163.4M | -$79.3M | -4.6% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring MIRM)
- ✓Live walkthrough of MIRM's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
MIRM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +54.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MIRM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MIRM. Explore sector supply chains on /butterfly.
MIRM Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Mirum Pharmaceuticals Inc. (MIRM)?
In FY 2025 (10-K), MIRM converted $521.3M of revenue into a 44% gross margin, 0% operating margin, and $54.9M in free cash flow (10.5% FCF margin).